Ablynx NV (ABLX.BR)
7 Mar 2014
|Market Cap (Mil.):||€469.89|
|Shares Outstanding (Mil.):||49.00|
BRUSSELS, Feb 27 - Ablynx NV : * Says FY revenue growth of 34 pct to 35.9 million euros * Says net loss for the period reduced by 32 pct to 19.5 million euros (2012: 28.5 million euros) * Says fourfold increase in cash-income from collaborations to 157.6 million euros (2012: 36.5 million euros)
BRUSSELS, Feb 27 - Belgian biopharmaceutical company Ablynx reported a 34 percent rise in revenue in 2013 and ended the year with a large cash pile, although cautioned that it would burn through more of it this year than last.
BRUSSELS - Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.3 billion) to develop ways of triggering the body to fight cancer by itself.
BRUSSELS, Feb 3 - Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.29 billion) to develop potential new treatments for cancer.
BRUSSELS, Feb 3 - Ablynx NV : * Announces worldwide cancer immunotherapy discovery collaboration and licensing agreement with Merck * Collaboration, licensing agreement is focused on the discovery and development of several predefined nanobody candidates * Co will receive an upfront payment of 20 mln euros; up to 10.7 mln euros in research funding during the initial three year * Is eligible to receive development, regulatory and commercial milestone payments on achieved sales thre
BRUSSELS, Jan 13 - Ablynx NV : * Phaseii data on anti-vWF Nanobody, Caplacizumab,to treat acquired thrombotic thrombocytopenic purpura, expected in H1 2014 * Says if the results are promising, a phase III study is anticipated to commence in 2015
* Ablynx CEO expects development deals in emerging markets
BRUSSELS, Nov 25 - Ablynx NV : * Sofinnova partners notified that they have dropped below the 3 pct threshold and have sold their complete stake in Ablynx * Biotech Value Fund Partners LP and Biotech Value Fund Inc now hold 2,554,524 Ablynx shares which is 5.23 pct of co's shares
BRUSSELS, Nov 18 - Belgian biotech group Ablynx said on Monday that Paris-based venture capital firm Sofinnova Partners sold its 7.02 percent stake in the group in a private placement worth some 22 million euros ($29.76 million).
BRUSSELS, Nov 18 - Belgian biotech group Ablynx said on Monday that Paris-based venture capital firm Sofinnova Partners, which has a 7.02 percent stake in the group, had launched a private placement to sell shares in the company.
Earnings vs. Estimates
Analyst Research Reports
Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.